



## Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report

**Oslo, Norway, February 5, 2025** – Lytix Biopharma AS (“Lytix” or the “Company”) will release its fourth quarter 2025 financial results and publish its second half 2025 financial report on Thursday, February 12, 2025.

Join us for a live webcast presentation featuring **CEO Øystein Rekdal** and **CFO Gjest Breistein**, where they will discuss the Q4 results and provide key insights.

**Date:** Thursday, February 12, 2025

**Time:** 10:00 AM CET

### **Q&A Session:**

We welcome your questions in advance. Please send them to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com), and they will be addressed during the Q&A session following the presentation.

### **Webcast Details:**

The presentation and Q&A session will be conducted in English. You can view the live event by registering here: [http://qcnl.tv/p/Bs5cUOyZ0tu\\_8Vd3OK5\\_Q](http://qcnl.tv/p/Bs5cUOyZ0tu_8Vd3OK5_Q)

### **Missed the Live Session?**

A recording of the presentation will be available shortly after the event on our financial reports page: <http://www.lytixbiopharma.com/financial-reports>

### **For more information, please contact:**

Gjest Breistein, CFO

+47 952 60 512

[gjest.breistein@lytixbiopharma.com](mailto:gjest.breistein@lytixbiopharma.com)

### **About Lytix:**

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemotide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.

For more information, visit [www.lytixbiopharma.com](http://www.lytixbiopharma.com).